Research programme: antibody-drug conjugates - Millennium/Seattle Genetics

Drug Profile

Research programme: antibody-drug conjugates - Millennium/Seattle Genetics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium
  • Developer Seattle Genetics; Takeda Oncology
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
  • 16 Mar 2011 Millennium exercises an option to designate a second antigen target under the existing collaboration with Seattle Genetics for the development of antibody conjugates for the treatment of cancer
  • 07 Apr 2009 Millennium and Seattle Genetics enter into a worldwide agreement for the development of antibody conjugates for the treatment of cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top